Marinus Pharma (MRNS) – FDA
-
Marinus Pharma (MRNS) phase 3 RAISE trial did not meet pre-defined stopping criteria at the interim analysis
-
Marinus Pharma (MRNS) Announces European Commission Approval of ZTALMY for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MRNS Stock Lookup